, 12.0% 3rd-party Products, 10.3% Note: Pie charts represent annual sales derived from individual product groups as a % of domestic sales in respective finanical reporting period Our product strategies and

Company and its subsidiary for Quarter 3 of 2019 ending on 30 September 2019 as follows; Statements of Comprehensive Income Revenue from medical treatment The Company generated the revenue from medical

subsidiary for Quarter 1 of 2020 ending on 31 March 2020 as follows; Statements of Comprehensive Income Revenue from medical treatment The Company generated the revenue from medical treatment for the 1st

the period of the companywas 5.12 million Baht. The changes are explained as follows; Sales Revenues: For the 2d quarter ot 2017 ,the Company generated a revenue trom sales of 39.04 million Baht

; Sales Revenues: For the 3th quarter of 2017, the Company generated a revenue from sales of 41.84 million Baht, increasing by 27.27% when compared to the same period in the previous year, which had a total

, the Company generated a revenue from sales of 41.84 million Baht, increasing by 27.27% when compared to the same period in the previous year, which had a total revenue of 32.87 million Baht. This

changes are explained as follows; Sales Revenues: For the year of 2017, the Company generated a revenue from sales of 167.41 million Baht, increasing by 27.39% from the previous year, which had a total

which was reported at 31%. In addition, the Company generated revenue from sale of vacant land of THB 562.51 million. - Revenue from rent and service was THB 62.12 million, an increase of THB 12.95

Baht 1.60 million. This was mainly caused by the lower revenues derived from fee and service income, interest on margin loans and return on financial instruments. However, KT ZMICO’s operating expense

highest transaction value equals 0.31 percent based on the value of consideration basis. The highest transaction value is derived from this method of calculation, whereby the calculation is based on the